Joshua Ellenhorn is an Oncology physician affiliated with Cedars-Sinai Medical Center. OpenAlex indexes 164 publications with 5,752 citations (h-index 41); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8635 W 3rd St Ste 880w
Los Angeles, CA 900486155
Telephone
310-289-1518Provider last certified this registry record 16 Dec 2025.
Clinical trials
- Circadian Thermal Sensing to Detect Breast Disease
Sponsor: Cyrcadia Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
23 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Davol Inc.Program year20251 payment
- Medtronic, Inc.Program year20251 payment
- MIMEDX Group, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
59.3%Opioid Agonist59.3%Hydrocodone-Acetaminophen100%Part D≥16 patientsMetabolism & gastrointestinal
40.7%Antidiarrheal microorganisms40.7%Creon100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 1997–2008 per NIH RePORTER. The latest:
- EVALUATION OF THE USE OF POXVIRUS VACCINES TO STIMULATE P53 SPECIFIC IMMUNITY
University of Southern California
FY2008$1,201M01RR000043 - EVALUATION OF THE USE OF POXVIRUS VACCINES TO STIMULATE P53 SPECIFIC IMMUNITY
University of Southern California
FY2007$968M01RR000043 - CLINICAL EVALUATION OF A POXVIRUS VACCINE TARGETING P53
Beckman Research Institute/city of Hope
FY2006$293,338R21CA114889
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Beth Karlan, MD
Cedars-Sinai Medical Center
Raj Makkar, MD
Cedars-Sinai Medical Center
Paul Noble, MD
Cedars-Sinai Medical Center
Stephen Freedland, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”